Anti-KLF4 抗体
Anti-KLF4 antibody
5
(4 Reviews)
|
(47 Publications)
Rabbit Polyclonal KLF4 antibody. Suitable for WB, IHC-P and reacts with Human, Mouse, Rat samples. Cited in 47 publications. Immunogen corresponding to Synthetic Peptide within Human KLF4.
別名を表示する
EZF, GKLF, KLF4, Krueppel-like factor 4, Epithelial zinc finger protein EZF, Gut-enriched krueppel-like factor
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-KLF4 antibody (AB106629)
Immunohistochemical analysis of paraffin-embedded human colon tissue labeling KLF4 with ab106629 at 2 µg/mL. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH 6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-KLF4 antibody (AB106629)
Immunohistochemical analysis of paraffin-embedded rat colon tissue labeling KLF4 with ab106629 at 2 µg/mL. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH 6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-KLF4 antibody (AB106629)
Immunohistochemical analysis of paraffin-embedded mouse colon tissue labeling KLF4 with ab106629 at 2 µg/mL. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH 6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
- WB
Supplier Data
Western blot - Anti-KLF4 antibody (AB106629)
1 h incubation at RT in 5% NFDM/TBST. ab106629 detected the expression of KLF4 in MCF-7 cells, but not in Jurkat cells, which matches the RNA expression pattern in these two cell lines based on Human Protein Atlas data.
All lanes:
Western blot - Anti-KLF4 antibody (ab106629) at 1 µg/mL
Lane 1:
MCF-7 cell lysate at 15 µg
Lane 2:
Jurkat cell lysate at 15 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG HRP conjugate at 1/10000 dilution
false
- WB
CiteAb
Western blot - Anti-KLF4 antibody (AB106629)
Western Blotting using Anti-KLF4 antibody, ab106629. Publication image from Yang, G. S. et al., 2020, Theranostics, 32685020. Legend direct from paper.
Downregulation of KLF4 by Sal-miR-1 and 3 increases NMHC IIA expression level. (A) A subset of the differentially expressed mRNAs detected in pcDNA3.1- or pcDNA3.1-KLF4-transfected VSMCs with microarray analysis was selected and summarized. (B) A schematic map of the -1843 to +42 bp region of the NMHC IIA promoter showing the positions of KLF4-binding sites. VSMCs were transfected with pcDNA3.1 or pcDNA3.1-KLF4 for 24 h, and then formaldehyde-cross-linked chromatin was extracted and immunoprecipitated with anti-KLF4 antibody. Nonimmune IgG was used as negative control for immunoprecipitation. Immunoprecipitated DNA containing KLF4 binding sites was amplified by PCR using mouse NMHC IIA promoter-specific primers. (C) VSMCs were co-transfected with KLF4 expression plasmids and NMHC IIA promoter-reporter plasmids for 24 h. Luciferase activity was measured using the dual luciferase reporter assay system. (D-G) VSMCs were transfected with pcDNA3.1-KLF4, si-KLF4 or their corresponding control for 24 h. The expression of KLF4 and NMHC IIA was analyzed by qRT-PCR (D-G) and Western blot (E-F). (H) VSMCs were transfected with Sal-miR-1+3 and/or si-OTUD7B for 24 h. The expression of OTUD7B, KLF4 and NMHC IIA was analyzed by Western blotting. All results are presented as the mean±SEM from 3 independent experiments (n=3). Student's t-test : *P<0.05, **P<0.01, ***P<0.001 versus the corresponding control.
false
- WB
CiteAb
Western blot - Anti-KLF4 antibody (AB106629)
Western Blotting using Anti-KLF4 antibody, ab106629. Publication image from Yang, G. S. et al., 2020, Theranostics, 32685020. Legend direct from paper.
OTUD7B downregulation by Sal-miR-1 and 3 attenuates KLF4 protein levels. (A) Bioinformatics analysis of the proteins interacting with OTUD7B by three protein-protein interactions databases. Images were obtained from the Cytoscape, inBio-Map and Genemania online database (Cytoscape : http : //apps.cytoscape.org/apps/agilentliteraturesearch; inBio-Map : https : //www.intomics.com/inbio/map.html#search; Genemania : http : //genemania.org). The potential proteins associated with OTUD7B were marked. (B) VSMCs were treated with 0.03 mg/mL cycloheximide (CHX), along with or without MG132 treatment. Cells were harvested at the indicated times, and KLF4 was detected by Western blotting, whereas band intensities that were measured are shown on the right. (C) VSMCs were transfected with si-Ctl or si-OTUD7B for 24 h, and the expression of OTUD7B and KLF4 was analyzed by Western blotting. (D) VSMCs were transfected with pcDNA3.1 or pcDNA3.1-OTUD7B for 24 h, and the expression of OTUD7B and KLF4 was analyzed by Western blotting. (E) VSMCs were transfected with pcDNA3.1-OTUD7B, si-OTUD7B or their corresponding control for 24 h. KLF4 expression was analyzed by qRT-PCR. (F) The Flag-tagged KLF4 expression vectors alone or together with GFP-tagged OTUD7B expression vectors were transiently transfected into HEK293A cells, after 24 h of transfection, 0.03 mg/mL CHX was added to each plate, and then incubated for 0, 2, 4, 6, and 8 h, respectively. Protein levels of KLF4 and OTUD7B were detected by Western blotting. (G) VSMCs were transfected with pcDNA3.1-OTUD7B or pcDNA3.1 for 24 h, and then anti-OTUD7B immunoprecipitates (IP) were analyzed by Western blot (WB) for OTUD7B and KLF4 co-sedimentation. IgG was used as negative control. (H) VSMCs were transfected with pcDNA3.1-OTUD7B, si-OTUD7B or their corresponding control for 24 h, and then treated with MG132 for 6 h. KLF4 was immunoprecipitated with anti-KLF4 antibody and immunoblotted with anti-ubiquitin antibody. (I) HEK293A cells were transfected for 24 h with pcDNA3.1-OTUD7B, si-OTUD7B or their corresponding control, and then treated with MG132 for 6 h. Cell lysates were incubated with anti-KLF4 antibody, and the immunoprecipitates were analyzed by immunoblotting with anti-ubiquitin antibody. All experiments were performed three independent experiments, and the results are presented as the mean ± SEM. Repeated Measures ANOVA or Student's t-test : **P<0.01, ***P<0.001 versus the corresponding control.
false
Reactivity data
製品の詳細
出荷温度及び保存条件
製品の状態
精製方法
精製に関する特記事項
バッファー組成
出荷温度
短期保存期間
短期保存温度
長期保存温度
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
KLF4 impacts cell differentiation and proliferation through its role as a transcription factor. It functions within several cellular complexes and interacts with other transcription factors to modulate gene expression. KLF4 regulates stem cell maintenance by influencing gene networks involved in self-renewal and differentiation contributing particularly to pluripotency in embryonic stem cells.
Pathways
The transcriptional activity of KLF4 integrates into key signaling pathways like the Wnt/β-catenin and Notch pathways. Within the Wnt/β-catenin pathway KLF4 may cooperate with β-catenin and TCF/LEF transcription factors to modulate gene targets. Similarly in the Notch signaling pathway KLF4 interacts with pathway components to influence cell fate decisions. These interactions highlight KLF4's central role in orchestrating complex signaling networks.
製品プロトコール
- Visit the General protocols
- Visit the Troubleshooting
ターゲットの情報
文献 (47)
Recent publications for all applications. Explore the full list and refine your search
Acta histochemica et cytochemica 58:45-57 PubMed40535470
2025
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in pharmacology 16:1548660 PubMed40365315
2025
Applications
Unspecified application
Species
Unspecified reactive species
Nature aging 4:546-567 PubMed38553564
2024
Applications
Unspecified application
Species
Unspecified reactive species
Pharmacology 109:34-42 PubMed38011839
2023
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 14:5360 PubMed37660071
2023
Applications
Unspecified application
Species
Unspecified reactive species
iScience 25:105194 PubMed36217548
2022
Applications
Unspecified application
Species
Unspecified reactive species
Bioactive materials 21:69-85 PubMed36017070
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell reports 40:111240 PubMed36001968
2022
Applications
Unspecified application
Species
Unspecified reactive species
Gene 842:146800 PubMed35961432
2022
Applications
Unspecified application
Species
Unspecified reactive species
Cell death discovery 8:166 PubMed35383144
2022
Applications
Unspecified application
Species
Unspecified reactive species
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com